A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation

Abatacept is the first drug in a new class of disease-modifying anti-rheumatic drugs known as selective modulators of T-cell costimulation. The efficacy of abatacept in the treatment of rheumatoid arthritis (RA) has been shown in several clinical phase II and phase III trials, wherein abatacept was...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Wiener medizinische Wochenschrift 2009-02, Vol.159 (3-4), p.70
Hauptverfasser:	Dejaco, Christian, Duftner, Christina, Wipfler, Edith, Schirmer, Michael
Format:	Artikel
Sprache:	ger
Schlagworte:	Abatacept Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Disease Progression Drug Therapy, Combination Humans Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Infliximab Lymphocyte Activation - drug effects Lymphocyte Activation - immunology Methotrexate - adverse effects Methotrexate - therapeutic use Randomized Controlled Trials as Topic T-Lymphocytes - drug effects T-Lymphocytes - immunology Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!